Clinical Trial

Assess Sacubitril/Allisartan and Amlodipine in Patients With Essential Hypertension Uncontrolled With Amlodipine

Name: Assess Sacubitril/Allisartan and Amlodipine in Patients With Essential Hypertension Uncontrolled With Amlodipine — clinical trial record (NCT07704684)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Completed Phase 3

View on ClinicalTrials.gov →

Summary

The main objective of the study will be to assess the efficacy and safety of Sacubitril/Allisartan (240mg) and Amlodipine (5mg) in patients with essential hypertension uncontrolled after 4-week treatment with Amlodipine (5mg).

Trial Details

NCT Number	NCT07704684
Lead Sponsor	Shenzhen Salubris Pharmaceuticals Co., Ltd.
Conditions	Essential Hypertension
Enrollment	376 participants
Start Date	2023-06-28
Primary Completion	2025-08-26 (estimated)
Study Completion	2025-09-08 (estimated)
Updated on ClinicalTrials.gov	2026-07-15